TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8(+) T cell and XCR1(+) dendritic cell spatial co-localization

BACKGROUND: T cell immunoglobulin and mucin domain containing−3 (TIM-3) blocking antibodies are currently being evaluated in clinical trials for solid and hematological malignancies. Despite its identification on T cells, TIM-3 is predominantly expressed by myeloid cells, including XCR1(+) type I co...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardner, Alycia, de Mingo Pulido, Álvaro, Hänggi, Kay, Bazargan, Sarah, Onimus, Alexis, Kasprzak, Agnieszka, Conejo-Garcia, Jose R, Rejniak, Katarzyna A, Ruffell, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734033/
https://www.ncbi.nlm.nih.gov/pubmed/34987021
http://dx.doi.org/10.1136/jitc-2021-003571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734033/
https://www.ncbi.nlm.nih.gov/pubmed/34987021
http://dx.doi.org/10.1136/jitc-2021-003571

Ejemplares similares